Herbal, Vitamin & Dietary Supplement Contract Manufacturing

ANDA - Abbreviated New Drug Applications

While Vesta has sustained profitable growth since its inception, the future of the company lies in the pursuit of generic drugs. Vesta seeks to become a pro-active generic pharmaceutical manufacturer dedicated to creating value with quality generic drugs. Millions of consumers already utilize generics to treat a range of illnesses and diseases. Countless more consumers continue to wait for more affordable access to generics to treat their serious medical conditions, and Vesta is strategically situated to deliver a cost effective and safe product.

Vesta believes that its generic pharmaceutical manufacturing capacity will be of strategic significance, paralleling the needs of an emerging and dynamically evolving generic industry deeply affected by trends of consolidation among managed care providers, large pharmacy chains, wholesalers and other large-scale buyers. We understand and appreciate the compromise that the generic market strikes between pioneer drug companies seeking to protect the investment in research and technology, and the interests of consumers who benefit from generic products due to increased competition and reduced prices.

Today, millions of consumers are using generics to treat a variety of medical conditions, all rigorously tested by the FDA and manufactured and inspected under the same strict guidelines as a brand name drug. The generic industry is growing at more than 7.8%, a pace that is faster than the world pharmaceutical market. In the Unites States alone, generic pharmaceutical manufacturer sales eclipsed $58.5 billion. According to a 1998 study conducted by the Congressional Budget Office, generic drugs save consumers between $8 billion and $10 billion each year. Our goal at Vesta is to provide high quality, low-cost products ' and it's clear from these studies that with generics, Americans, and consumers around the globe, can save substantially on their prescription drugs. The generic drug market was created some 25 years ago by the Hatch-Waxman Act, the goal being to provide consumers with safe, less expensive drugs that were the same as the counterpart brand product. Generics have certainly provided substantial savings to the U.S. healthcare system, and the Vesta team is dedicated to continuing the work of providing generic alternatives to consumers.

CLICK HERE: To View Our VESTA- Brochure